Dyadic International (NASDAQ:DYAI), Inc. is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.
The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast. This enhanced productivity makes the system particularly attractive for contract development and manufacturing organizations (CDMOs), pharmaceutical companies and industrial partners looking to optimize yields of monoclonal antibodies, vaccine antigens, therapeutic enzymes and specialty proteins. Beyond human health, Dyadic pursues collaborations in animal health, nutraceuticals and sustainability sectors, where its fermentation-based approach can be applied to next-generation bioactive ingredients and environmentally friendly enzyme solutions.
Since its inception, Dyadic has pursued a model centered on technology partnerships and licensing arrangements to extend the reach of its C1 platform across global markets. The company went public on the Nasdaq exchange under the symbol DYAI and has since established research and commercial alliances in North America, Europe and Asia. Dyadic’s management team comprises experienced biotechnology and industrial fermentation professionals, guiding the company’s strategy to expand its applications pipeline and secure partnerships with leading biomanufacturers and specialty chemical producers worldwide.
